Yue Guo, Sisi Zhang, Jamie Ash, Stacey Helming, Rachel Mullen, Xuening Hu, Qingyan Hu, Jing Wang, Tse-Hong Chen, Shao-Chun Wang, Douglas Kamen, Biao Shen, Hui Xiao, Ning Li
{"title":"Utilizing Octanoic Acid to Quantitatively Assess the Oxidation Status of PS80.","authors":"Yue Guo, Sisi Zhang, Jamie Ash, Stacey Helming, Rachel Mullen, Xuening Hu, Qingyan Hu, Jing Wang, Tse-Hong Chen, Shao-Chun Wang, Douglas Kamen, Biao Shen, Hui Xiao, Ning Li","doi":"10.1007/s11095-025-03908-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to address the gap in research concerning the stability of polysorbate (PS) in placebo samples, as opposed to drug products. While PS is a critical excipient in protein drug formulations, its stability in placebo samples has been less explored. Notably, PS in placebo samples is more susceptible to oxidation rather than hydrolysis, even at low temperatures like 5℃. The study seeks to provide a quantitative measure for PS oxidation, which has traditionally been described in vague terms.</p><p><strong>Method: </strong>The research identified octanoic acid as an oxidative product of PS80, which can serve as a reliable marker for PS80 oxidation. This marker enables the detection of early signs of oxidation and facilitates a quantitative description of the oxidation status, regardless of the stress conditions and incubation times. The method's accuracy and precision were validated to be within 15%, aligning with industry standards.</p><p><strong>Results: </strong>The use of octanoic acid as a marker successfully indicates the oxidation status of PS80, offering a quantitative approach to assess PS80 stability. This method provides a clearer understanding of the shelf-life of placebo products concerning PS80 stability.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"1397-1407"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-025-03908-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The study aims to address the gap in research concerning the stability of polysorbate (PS) in placebo samples, as opposed to drug products. While PS is a critical excipient in protein drug formulations, its stability in placebo samples has been less explored. Notably, PS in placebo samples is more susceptible to oxidation rather than hydrolysis, even at low temperatures like 5℃. The study seeks to provide a quantitative measure for PS oxidation, which has traditionally been described in vague terms.
Method: The research identified octanoic acid as an oxidative product of PS80, which can serve as a reliable marker for PS80 oxidation. This marker enables the detection of early signs of oxidation and facilitates a quantitative description of the oxidation status, regardless of the stress conditions and incubation times. The method's accuracy and precision were validated to be within 15%, aligning with industry standards.
Results: The use of octanoic acid as a marker successfully indicates the oxidation status of PS80, offering a quantitative approach to assess PS80 stability. This method provides a clearer understanding of the shelf-life of placebo products concerning PS80 stability.
期刊介绍:
Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to:
-(pre)formulation engineering and processing-
computational biopharmaceutics-
drug delivery and targeting-
molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)-
pharmacokinetics, pharmacodynamics and pharmacogenetics.
Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.